Clinical effects of buspirone in social phobia, a double-blind placebo controlled study

Treatment of social phobia with the dopamine agonist pergolide

“…For instance, dopamine reuptake inhibitors might be more effective than direct dopamine agonists if the clinical benefits are more related to or include modifications of receptor density or sensitivity rather than direct stimulation of postsynaptic dopamine receptors. For example, the serotonin 5HT1A receptor agonist, buspirone, appears to be ineffective for social phobia [van Vliet et al, 1997], while marked benefits have been associated with the use of the serotonin reuptake inhibitors [Stein et al, 1999]. Both dopaminergic and serotonergic abnormalities have been implicated in the pathophysiology of social phobia; medications which affect both systems may be particularly beneficial.…”

A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder

“…Theoretically, analogous considerations may apply in SAD, but the literature in this regard is very sparse. One small, open-label study showed that buspirone augmentation of an SSRI was often useful in SAD [52], although buspirone monotherapy does not appear to be useful in this condition [53]. A placebocontrolled study of paroxetine plus clonazepam or placebo provided some evidence for the benefit of treating SAD patients with this combination of agents [54].…”

The use of buspirone in clinical practice

“…При этом отмечен эффект буспирона в дозе 15-60 мг/сут как в отношении вербаль-ной (60%), так и физической (90%) агрессии [9][10][11][12].…”